Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Hendrix

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 18, 2022
Examining older adults with neuroatypical conditions for MCI/dementia: Barriers and recommendations of the Neuroatypical Conditions Expert Consultative PanelMatthew P Janicki, James A Hendrix, Philip McCallion, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 10, 2017
Is cognitive decline measurable in preclinical Alzheimer's disease?Sandra Weintraub, Christopher Randolph, Lisa Bain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 6, 2017
Potential roles of digital technologies in clinical trialsSara Czaja, Michael Gold, Lisa J Bain, et al.
Frontiers in Pediatrics|February 23, 2023
Weight management recommendations for youth with Down syndrome: Expert recommendationsLauren T Ptomey, Nicolas M Oreskovic, James A Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 8, 2018
National Institute on Aging - Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's diseaseDavid S Knopman, Eric R Siemers, Lisa J Bain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 8, 2016
Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's diseaseKrista L Lanctôt, Brendon P Boot, Lisa J Bain, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2013
Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamideZhongli Gao, William J Hurst, Etienne Guillot, et al.
Bioorganic & Medicinal Chemistry|January 12, 2015
Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategyZhongli Gao, William J Hurst, Daniel Hall, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depressionZhongli Gao, William J Hurst, Werngard Czechtizky, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disordersZhongli Gao, William J Hurst, Werngard Czechtizky, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 18, 2022
Examining older adults with neuroatypical conditions for MCI/dementia: Barriers and recommendations of the Neuroatypical Conditions Expert Consultative PanelMatthew P Janicki, James A Hendrix, Philip McCallion, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 10, 2017
Is cognitive decline measurable in preclinical Alzheimer's disease?Sandra Weintraub, Christopher Randolph, Lisa Bain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 6, 2017
Potential roles of digital technologies in clinical trialsSara Czaja, Michael Gold, Lisa J Bain, et al.
Frontiers in Pediatrics|February 23, 2023
Weight management recommendations for youth with Down syndrome: Expert recommendationsLauren T Ptomey, Nicolas M Oreskovic, James A Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 8, 2018
National Institute on Aging - Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's diseaseDavid S Knopman, Eric R Siemers, Lisa J Bain, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 8, 2016
Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's diseaseKrista L Lanctôt, Brendon P Boot, Lisa J Bain, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2013
Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamideZhongli Gao, William J Hurst, Etienne Guillot, et al.
Bioorganic & Medicinal Chemistry|January 12, 2015
Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategyZhongli Gao, William J Hurst, Daniel Hall, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2013
Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depressionZhongli Gao, William J Hurst, Werngard Czechtizky, et al.
Bioorganic & Medicinal Chemistry Letters|October 1, 2013
Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disordersZhongli Gao, William J Hurst, Werngard Czechtizky, et al.
Pageof 3